Navigation Links
Drug study shows improvement in major orthopedic surgery care
Date:7/9/2010

Hamilton, ON (July 9, 2010) An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.

The follow-up analysis of three recently completed international clinical studies on short-term venous thromboembolism (VTE) protective medicine in patients undergoing major orthopedic surgery demonstrated that the ultra-low-molecular-weight heparin semuloparin reduced the incidence of VTE and all-cause death by 25 per cent compared to the commonly used therapy drug enoxaparin (a low-molecular-weight heparin).

Patients undergoing major orthopedic surgery are at increased risk of developing a dangerous blood clot that blocks veins, which is known as venous thromboembolism (VTE). Without treatment, the incidence of confirmed deep-vein thrombosis, blood clots within the veins of the legs and pelvis, is up to 40 to 60 per cent following major orthopedic surgery.

"This is a potential advance in orthopedic surgery compared to current VTE prophylaxis options," said Turpie, a professor of medicine at the Michael G. DeGroote School of Medicine at McMaster.

The favourable benefit-to-risk profile observed with semuloparin compared to enoxaparin in the classic major orthopedic surgery model supports the further evaluation of semuloparin as VTE preventative therapy in other areas including oncology, as VTE is a known complication in patients with cancer. Patients suffering from cancer have a four to seven fold greater risk for VTE.

Turpie's meta-analysis study reports results from 4,479 patients recruited in three orthopedic surgery studies in hip replacement (SAVE HIP), hip fracture (SAVE HIP-FRA) and knee replacement (SAVE KNEE). The objective of the three studies was to assess once-daily preventative treatment with semuloparin (20 mg) compared to enoxaparin (40 mg daily in hip, and 30 mg twice-daily for knee) for seven to 10 days.

The results of the SAVE program in orthopedic surgery were presented today at the 21st International Congress of Thrombosis in Milan, Italy, and organized by the Mediterranean League Against Thromboembolic Diseases.

Turpie is chairing the steering committee for the SAVE program, an international series of studies. The SAVE program is supported by sanofi-aventis, producer of semuloparin.

Semuloparin's benefit-to-risk profile in cancer is currently being investigated in two ongoing phase three clinical studies. SAVE ONCO evaluates semuloparin in patients with cancer undergoing chemotherapy. SAVE ABDO assesses the benefits of semuloparin in major abdominal surgery, mainly cancer surgery.


'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

Related medicine news :

1. Study suggests link between scleroderma, cancer in certain patients
2. Fish Oil Supplements Linked to Lower Risk of Breast Cancer: Study
3. Study finds patients benefit from thorough discussion of recommended operations
4. Many Docs Deliver Cancer Diagnosis Badly: Study
5. Study: Higher-protein diets support weight loss, but may lower bone density in postmenopausal women
6. Legalizing marijuana in California would lower the price of the drug and increase use, study finds
7. Study shows race, not experience, impacts hiring in sports world
8. 1 in 4 Californian children have never seen a dentist, study finds
9. Understanding Back Pain May Improve Management, Study Suggests
10. SDI Reports: Novo Nordisk Takes Top Ranking Among Endocrinologists, According To Pharmaceutical Company Image Study
11. The Framingham Heart Study -- global impact, ongoing influence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... 2017 , ... NexTec Group has been selected as a member of the ... accomplishments in the field of midmarket financial software. , Members of the VAR Stars ... is not based on revenue and those firms chosen represent a wide range of ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the ... There are also new avenues for purchase. , The 2017 edition has wide jaws ... issues for the older boomers as well as diabetics. This handle is reinforced for extra ...
(Date:1/15/2017)... ... January 15, 2017 , ... San Francisco Magazine ... Bay Area counties for 2017. Almost 1,000 nominations were submitted and a little ... process. Results were announced the magazine’s January 2017 issue . , Under ...
(Date:1/15/2017)... , ... January 15, 2017 , ... ... in Montclair, NJ is pleased to announce that it will be assisting HackensackUMC ... in Montclair and Glen Ridge townships, servicing all surrounding towns. The firm will ...
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... AgileMinder develops ... , The Emoji Scale is now available on Apple as a fun, free ... ratings simply by choosing one of the ten color coded values on The Emoji ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... Jan. 13, 2017  Alfalfa, cattle, leafy greens and rosy ... sampling film , which emphasizes the food industry,s shift from ... how COPAN,s Swab Rinse Kit ... surface sampling process in the wake of the new ... COPAN is expanding the U.S. production of ...
(Date:1/13/2017)... Pa. , Jan. 13, 2017  Secretary of ... of students, professors, and community members at Misericordia University ... opioid epidemic in Pennsylvania . ... crisis I,ve seen so far in my professional career," ... has been hit hard by heroin and ...
(Date:1/13/2017)... BOISE, Idaho , Jan. 12, 2017 /PRNewswire/ ... status by Accreditation Commission for Health Care (ACHC) ... the largest national food and drug chain with ... service for pharmacy patients. Accreditation by ... meeting national standards to facilitate a higher level ...
Breaking Medicine Technology: